It doesn't take two: The Tipline for 18 June 2019

As the healthcare industry remains under scrutiny in the US, Pfizer has marched ahead with an $11 billion merger that could reshape the cancer treatment landscape. Meanwhile, a US senator is calling on Congress to reorganise civil antitrust enforcement so that it is done under one roof and not split between two authorities.